Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bruker Announces European Launch of Toxtyper™

Published: Wednesday, September 26, 2012
Last Updated: Wednesday, September 26, 2012
Bookmark and Share
High-performance Toxtyper solution automatically analyzes for 850 toxicology target compounds in just 10 minutes.

At the annual conference of the DGKL (Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin), Bruker has announced the European launch of the novel, automated Toxtyper™ clinical mass spectrometry solution to meet the increasing demands for LC-MS/MS throughput and data quality in routine toxicology laboratories without the need for mass spectrometry expertise.

The Toxtyper solution provides faster and more reliable identification of toxins and drugs of abuse within 10 minutes at therapeutic and toxic levels.

Bruker developed the Toxtyper solution with a library of 850 compounds in close collaboration with Jürgen Kempf at the Institute of Forensic Medicine in Freiburg, Germany, and with Professor Denis Hochstrasser and Dr. Marc Fathi’s team at the Geneva University Hospital (HUG - Hôpitaux Universitaires de Genève) in Switzerland.

Toxtyper solution sets a new standard in LC-MS/MS identification without requiring method development or mass spectrometry expertise.

Results and libraries are easily transferable from lab to lab due to Bruker’s patented SmartFrag™ technology, an innovation that essentially removes variation and tuning from the MS/MS process.

SmartFrag uniquely positions Toxtyper as a best-in-class, robust solution for rapid adoption in routine and acute clinical toxicology.

Transferability and reproducibility of the novel Toxtyper solution were validated by an inter-laboratory ring test using 4 spiked test serum samples measured by 7 Toxtyper systems in 5 different laboratories.

A positive, correct identification rate of well over 90% was reported by all participants, confirming the easy adoption, high performance and transferability of the Toxtyper method.

The Toxtyper solution combines novel library identification algorithms and a high quality library of toxicological compounds with Bruker’s high-performance amaZon speed ion trap mass spectrometer coupled to an UHPLC system.

This efficient and robust system provides ultrafast identification of drugs and toxins, with better throughput, compound coverage, selectivity and more reliable identification than previous LC-only or LC-MS/MS based toxicology systems.

Key technologies to achieve such robust and reliable toxicology identification performance include the use of continuous, zero-delay positive/negative ion switching, high MS/MS specificity and -importantly - novel, on-the-fly MS3 product ion confirmation.

Jürgen Kempf of the Institute of Forensic Medicine in Freiburg, Germany commented: “The combination of a simple push-button solution with the performance of the trap technology makes the Toxtyper solution a valuable tool for routine and research forensics labs.”

Dr. Marc Fathi from the Geneva University Hospital (HUG - Hôpitaux Universitaires de Genève) commented: “We are using two Toxtyper systems for the routine toxicological screening of patients admitted to the emergency room and profit from the ease-of-use and fast result generation of this solution.”

In parallel, the routine applicability of the Toxtyper solution is evaluated together with PD Dr. Peter Findeisen at the Institute for Clinical Chemistry, Mannheim (UMM), who commented: “We are using the system for routine screening of patients that are admitted to the emergency room of the UMM with suspected intoxications. The specificity of the method and shortened turnaround times are rather impressive, and perfectly fit the demands for general unknown screening.”

The new Toxtyper solution builds on the success of the MALDI Biotyper, the very successful Bruker mass spectrometry solution which has transformed clinical microbiology identification in recent years with faster time-to-result (TTR), lower consumables cost and more differentiated species and strain information on over 4,000 strains in a high-quality IVD-CE microbial identification database.

The amaZon speed series of ion trap mass spectrometers delivers small molecule sensitivity in the femtogram region, Zero-Delay Alternating (ZDA™) polarity switching and outstanding scanning speed at 52,000 u/sec.

This performance allows one-shot, 10 minute analysis of basic and acidic compounds in a single UHPLC separation, delivering reliable Toxtyper identification with the fastest identification rate in the market.

The amaZon speed is a proven robust platform, ideal for multi-user environments, and supported by Bruker’s unique Compass OpenAccess software, a web-based client-server system that enables a push-button solution for automatic library searches.

The performance of the amaZon speed delivers excellent data quality for a range of additional clinical small molecule applications, such as quantitative therapeutic drug monitoring (TDM) by sensitive and fast LC-MS/MS methods in less than 5 minutes.

Novel software for automated assignment of structures to fragment ions offers metabolite identification and structure verification by MSn.

The Toxtyper initially is a ‘For Research Use Only’ solution available in Europe. For more information on amaZon speed, please visit www.bdal.com.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bruker Opens New Preclinical Imaging Center of Excellence for the Americas
Massachusetts Center will provide advanced development, demonstration and customer support capabilities for Bracer’s unique multimodal preclinical imaging systems portfolio.
Thursday, January 30, 2014
Bruker Announces Acquisition of Prairie Technologies
Acquisition strengthens Bruker Nano Surfaces Division's position in life science markets.
Friday, September 13, 2013
Bruker and ImaBiotech Announces Collaboration
Bruker to distribute ImaBiotech's Quantinetix software for quantitative MALDI imaging.
Friday, June 21, 2013
Bruker to Acquire Carestream’s Preclinical In-vivo Imaging Business
Transaction positions in-vivo products for long-term growth.
Monday, September 24, 2012
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Development in Preventing Macular Degeneration
Following macular degeneration insight, promising drugs to prevent vision loss have been identified.
Improving Tumour Therapy with Nanoparticles
UHN nanoparticle called PEARLs is a promising utilisation of photo-thermal therapy for cancer treatment.
New Antidepressant Treatment Discovered
Scientists have demonstrated how gene therapy could lead to new treatments for depression.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!